Risk for cerebral venous thrombosis elevated after COVID-19 | The Daily Star
12:00 AM, April 18, 2021 / LAST MODIFIED: 12:28 AM, April 18, 2021

Health Bulletin

Risk for cerebral venous thrombosis elevated after COVID-19

Rates of cerebral venous thrombosis (CVT), also called cerebral venous sinus thrombosis, are significantly higher among people with COVID-19 than in the general population or in mRNA vaccine recipients, suggests an unpublished study.

In patients with COVID-19, the absolute risk for CVT in the 2 weeks after diagnosis was 39 events per million people — significantly higher than the risk among influenza patients (0 per million) or mRNA vaccine recipients (4.1 per million). This was also higher than the risk among patients who have received the AstraZeneca adenovirus vaccine (5.0 per million at last count of the European Medicines Agency's monitoring system).

For all latest news, follow The Daily Star's Google News channel.

The incidence of portal vein thrombosis (PVT) was similarly elevated in the COVID-19 group, compared with the other groups. Mortality rates for COVID-19 patients after a diagnosis of CVT or PVT were 20% and 18%, respectively.

The authors say, "The current data highlight the risk of serious thrombotic events in COVID-19, and can help contextualise and inform debate about the risk-benefit ratio for current COVID-19 vaccines."

Stay updated on the go with The Daily Star Android & iOS News App. Click here to download it for your device.

Grameenphone:
Type START <space> BR and send SMS it to 22222

Robi:
Type START <space> BR and send SMS it to 2222


Banglalink:
Type START <space> BR and send SMS it to 2225

Leave your comments

Top News

Top News

Top